MYP_009161
Basic Information
Dostarlimab
Anticancer
Immunology Immune modulation Immunomodulatory activity
Immunology Immunomodulation Immuno-oncology
Standard
443 amino acids
C2160H3324N566O675S17
Standard
Sequence
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSTISGGGSYTYYQDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASPYYAMDYWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
Physicochemical Analysis
48565.99 Da
6.74
-0.63
-1.44
-0.0014
-0.39
0.55
0.02
49.15
67.43
0.1016
76780.00
77405.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0187764 VERIFIED: NO
Provenance & Taxonomy
not reported [other]
Monoclonal antibody
Structure & Mods
cyclic peptide scaffold [Cyclic]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Anticancer Immuno-oncology
The mean terminal elimination half-life of dostarlimab is 25.4 days.[L33320]
RECORD: Rec_0311543 VERIFIED: NO
Provenance & Taxonomy
not reported [other]
Monoclonal antibody
Structure & Mods
cyclic peptide scaffold [Cyclic]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Anticancer Immunomodulatory Immuno-oncology
The mean terminal elimination half-life of dostarlimab is 25.4 days.[L33320]
RECORD: Rec_0402537 VERIFIED: NO
Provenance & Taxonomy
synthetic construct [Synthetic]
Monoclonal antibody
32630
Structure & Mods
cyclic peptide scaffold [Cyclic]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Anticancer Immuno-oncology
The mean terminal elimination half-life of dostarlimab is 25.4 days.[L33320]